PACS Group raised full-year 2026 revenue guidance to $5.95 billion to $6.05 billion and adjusted EBITDA guidance to $685 million to $695 million, citing strength in its existing portfolio and recent acquisitions.
PACS · PACS Group, Inc.
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Up next
Latest documents
PACS Group, Inc. reported nine-month net income of $217,829 thousand versus $131,676 thousand, while skilled nursing services revenue reached $4,206,010 thousand. It operated 355 facilities across 20 states as of September 30, 2026.
PACS Group, Inc. increased full-year 2026 Adjusted EBITDA guidance to $685 million to $695 million and revenue guidance to $5.95 billion to $6.05 billion. Third-quarter revenue was $1.50 billion and Adjusted EBITDA was $175.7 million.
PACS Group, Inc. announced Patrick J. Murphy will succeed John Mitchell as Chief Legal Officer and Secretary, effective September 21, 2026; Mitchell retired effective September 18, 2026.
Metrics snapshot
Useful current figures from the complete screener profile.
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
AI Brief
Q3 FY26 earnings call · Nov 4, 2026TL;DR. PACS raised full-year revenue and adjusted EBITDA guidance while reporting strong third-quarter earnings, same-store growth, cash generation and geographic expansion. Risks include acquisition mix and integration investment, higher stock-based compensation, policy challenges involving rates, regulation and minimum staffing, ongoing government investigations and unresolved material weaknesses.
- + Full-year 2026 revenue guidance increased to $5.95 billion-$6.05 billion from $5.75 billion-$5.85 billion.
- + Full-year 2026 adjusted EBITDA guidance increased to $685 million-$695 million from $640 million-$660 million.
- + Third-quarter adjusted EBITDA increased 33.6% to $175.7 million from $131.5 million.
- + Same-store skilled nursing revenue increased 6.4%, occupancy improved to 91.3% from 89.3%, and skilled mix increased.
- + Nine-month operating cash flow reached $583.1 million, supported by $707.4 million of liquidity and 0.2x net leverage.
- + Expansion into Florida and continued growth in Texas broadened the company's geographic reach and created new operating opportunities.
- − Newly acquired ADURAL facilities entered at lower occupancy and skilled mix, reducing certain consolidated averages.
- − General and administrative expense increased to $138.4 million from $102.5 million, including higher stock-based compensation of $45.3 million versus $12.5 million.
- − Newly acquired facilities require substantial upfront integration investment before operating improvements are realized.
- − Government investigations remain ongoing, with their timing and ultimate outcomes unpredictable.
- − Full remediation of material weaknesses still required effectiveness testing and confirmation by the end of 2026.
- − Management highlighted potential policy challenges involving rates, regulation and minimum-staffing requirements.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Actual patient days | 2,640,144 | the three months ended June 30, 2026 filing | — |
| Adjusted Earnings Per Share non-GAAP | $0.63 | the second quarter of 2026 | — |
| Adjusted EBITDA non-GAAP | $337.14M | Six Months Ended June 30, 2026 | — |
| Adjusted EBITDAR non-GAAP | 261.5M | the second quarter of 2026 | — |
GAAP → non-GAAP reconciliationAdjusted EBITDA 166.75M (non-GAAP)
+94.7M Rent - cost of services
= Adjusted EBITDAR 261.45M
|
|||
| Adjusted Net Income non-GAAP | $101.73M | Three Months Ended June 30, 2026 | — |
GAAP → non-GAAP reconciliationGAAP Net income attributable to PACS Group, Inc. 76.37M
+734K Acquisition related costs
+25.83M Stock-based compensation expense
+8.17M Legal and other costs
-9.38M Provision for income taxes on non-GAAP adjustments
= Adjusted Net Income 101.73M
|
|||
| Available liquidity | 756.6M | June 30, 2026 | — |
| Average daily rate - Medicaid (Total) | $342.98 | Three Months Ended June 30, 2026 | — |
| Average daily rate - Medicare (Total) | $956.75 | Three Months Ended June 30, 2026 | — |
| Average daily rate - Total | $505.35 | Six Months Ended June 30, 2026 | — |
| EBITDA non-GAAP | $132.02M | Three Months Ended June 30, 2026 | — |
GAAP → non-GAAP reconciliationGAAP Net income attributable to PACS Group, Inc. 76.37M
+6.04M Interest expense
+29.49M Provision for income taxes
+20.12M Depreciation and amortization
= EBITDA 132.02M
|
|||
| Mature facilities average CMS star rating | 4.5 | the second quarter of 2026 | — |
| Mature facilities occupancy | 93.8% | the second quarter of 2026 | — |
| Mature facilities skilled mix | 31.9% | the second quarter of 2026 | — |
| Non-cash rent expense | 10.21M | the three months ended June 30, 2026 filing | — |
| Number of facilities at period end | 284 | Three Months Ended June 30, 2026 | — |
| Number of operational beds at period end | 32,790 | Three Months Ended June 30, 2026 filing | — |
| Occupancy | 90.6% | the second quarter of 2026 | — |
| Occupancy rate (operational beds) | 90.4% | Three Months Ended June 30, 2026 | — |
| Operating healthcare facilities | 344 | As of today | — |
| Overall occupancy | 90.4% | the second quarter of 2026 | — |
| Overall skilled mix | 30% | the second quarter of 2026 | — |
| Patients served daily | 33,400 | current | — |
| Real estate investment | 190.8M | the first six months of 2026 | — |
| Same-store occupancy | 90.6% | the three months ended June 30, 2026 filing | — |
| Same-store skilled mix by patient days | 29.7% | the three months ended June 30, 2026 filing | — |
| Share of skilled nursing portfolio rated 4 or 5 stars | 83.6% | the second quarter of 2026 | — |
| Skilled mix by nursing patient days | 30% | Three Months Ended June 30, 2026 filing | — |
| Skilled mix by revenue | 50% | Three Months Ended June 30, 2026 | — |
| Skilled nursing facilities rated 4 or 5 stars | 239 | the second quarter of 2026 | — |
| Skilled nursing services revenue | $2.75B | Six Months Ended June 30, 2026 | — |
| Skilled nursing services revenue (same-store) | $2.69B | Six Months Ended June 30, 2026 | — |
| Skilled nursing services revenue change (same-store) | 6.9% | Six Months Ended June 30, 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Medical Care Facilities — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
PACS
this stock
PACS Group, Inc.
|
$7.67B | +25.9% | +29.3% | 27.6 | 2.7% |
|
HCA
HCA Healthcare, Inc.
|
$104.25B | +6.9% | +7.1% | 16.6 | 2.3% |
|
FSNUY
Fresenius SE & Co. KGaA
|
$33.34B | +3.3% | — | — | 0.0% |
|
THC
Tenet Healthcare Corp
|
$22.76B | +43.9% | +0.9% | 8.3 | 2.2% |
|
EHC
Encompass Health Corp
|
$13.83B | +32.8% | +10.5% | 22.0 | 3.7% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 3, 2026
- This year
- 16
PACS Group, Inc. reported nine-month net income of $217,829 thousand versus $131,676 thousand, while skilled nursing services revenue reached $4,206,010 thousand. It operated 355 facilities across 20 states as of September 30, 2026.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| PACS | -2.6% | +3.0% | +24.3% | +1.1% | +25.9% |
| SPY | +2.6% | -1.2% | +0.5% | -0.2% | +10.6% |
| vs SPY | -5.2% | +4.2% | +23.8% | +1.3% | +15.3% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.